416 related articles for article (PubMed ID: 25539816)
1. CD8+ T cells complement antibodies in protecting against yellow fever virus.
Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
3. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
[TBL] [Abstract][Full Text] [Related]
4. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
[TBL] [Abstract][Full Text] [Related]
5. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
[TBL] [Abstract][Full Text] [Related]
6. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.
Neves PC; Santos JR; Tubarão LN; Bonaldo MC; Galler R
PLoS One; 2013; 8(12):e81953. PubMed ID: 24324734
[TBL] [Abstract][Full Text] [Related]
7. Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.
Campi-Azevedo AC; Reis LR; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Antonelli LR; Fonseca CT; Costa-Pereira C; Souza-Fagundes EM; da Costa-Rocha IA; Mambrini JVM; Lemos JAC; Ribeiro JGL; Caldas IR; Camacho LAB; Maia MLS; de Noronha TG; de Lima SMB; Simões M; Freire MDS; Martins RM; Homma A; Tauil PL; Vasconcelos PFC; Romano APM; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():2192. PubMed ID: 31616412
[TBL] [Abstract][Full Text] [Related]
8. The early cellular signatures of protective immunity induced by live viral vaccination.
Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
[TBL] [Abstract][Full Text] [Related]
9. The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.
Watson AM; Lam LK; Klimstra WB; Ryman KD
PLoS Pathog; 2016 Jul; 12(7):e1005786. PubMed ID: 27463517
[TBL] [Abstract][Full Text] [Related]
10. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-induced protection against orthopoxvirus infection is mediated through the combined functions of CD4 T cell-dependent antibody and CD8 T cell responses.
Chaudhri G; Tahiliani V; Eldi P; Karupiah G
J Virol; 2015 Feb; 89(3):1889-99. PubMed ID: 25428875
[TBL] [Abstract][Full Text] [Related]
13. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.
Julander JG; Trent DW; Monath TP
Vaccine; 2011 Aug; 29(35):6008-16. PubMed ID: 21718741
[TBL] [Abstract][Full Text] [Related]
14. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
[TBL] [Abstract][Full Text] [Related]
15. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
16. Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans.
Schulz AR; Mälzer JN; Domingo C; Jürchott K; Grützkau A; Babel N; Nienen M; Jelinek T; Niedrig M; Thiel A
J Immunol; 2015 Nov; 195(10):4699-711. PubMed ID: 26459351
[TBL] [Abstract][Full Text] [Related]
17. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
[TBL] [Abstract][Full Text] [Related]
18. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.
van der Most RG; Harrington LE; Giuggio V; Mahar PL; Ahmed R
Virology; 2002 Apr; 296(1):117-24. PubMed ID: 12036323
[TBL] [Abstract][Full Text] [Related]
19. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.
Santos AP; Bertho AL; Dias DC; Santos JR; Marcovistz R
Mem Inst Oswaldo Cruz; 2005 May; 100(3):331-7. PubMed ID: 16113878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]